The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models.
about
Cancer of the Pancreas: Molecular Pathways and Current Advancement in TreatmentBiomarkers and Targeted Therapy in Pancreatic CancerFrom fly wings to targeted cancer therapies: a centennial for notch signalingInhibition of notch signaling in combination with Paclitaxel reduces platinum-resistant ovarian tumor growth.Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations.Cancer stem cells: involvement in pancreatic cancer pathogenesis and perspectives on cancer therapeutics.Notch signaling in serous ovarian cancer.Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application.Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future.Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function.Aberrant activation of Notch signaling in extrahepatic cholangiocarcinoma: clinicopathological features and therapeutic potential for cancer stem cell-like propertiesEZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter.Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.The Notch signaling pathway as a mediator of tumor survivalEmerging targets in pancreatic cancer: epithelial-mesenchymal transition and cancer stem cellsGenetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision MedicineThe canary in the coal mine: the growth of patient-derived tumorgrafts in mice predicts clinical recurrence after surgical resection of pancreatic ductal adenocarcinoma.The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancerProfiling of ileal carcinoids.Brief overview of selected approaches in targeting pancreatic adenocarcinoma.TTD consensus document on the diagnosis and management of exocrine pancreatic cancer.Concise Review: Pancreatic Cancer and Bone Marrow-Derived Stem Cells.Combined inhibition of Notch and JAK/STAT is superior to monotherapies and impairs pancreatic cancer progression.Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma.The matricellular protein CCN3 regulates NOTCH1 signalling in chronic myeloid leukaemia.Strong therapeutic potential of γ-secretase inhibitor MRK003 for CD44-high and CD133-low glioblastoma initiating cells.Targeting Notch signalling pathway of cancer stem cells.Expression of Notch receptors and their ligands in pancreatic ductal adenocarcinoma.
P2860
Q26740619-16F9F89B-BC66-47B2-BA82-ED30FE3F7497Q26752755-61C275A1-CA04-4CC9-B943-1DE4D03134ADQ27004534-5B39563D-15CF-4D27-A233-F1DE2612D261Q33851035-1E185296-FE06-4570-BB20-9EBDEC735866Q34017017-B4069ED7-11F2-4DF2-BEB9-465D5C89A5A6Q34067873-168D530E-8203-4F1A-A4AB-39B9EFA7428AQ34491211-8ECE0282-97AE-429F-B218-2C2EDAB2A9D4Q34712645-F6383044-A9A1-4378-9CED-528EE9598420Q35604577-6E9F15AB-C7F3-40B2-8F86-F4ADE2F5247AQ35958099-7C909D43-7EA6-46BC-BF04-5C45169ED9B4Q36184732-4CDD0FF5-17F9-481D-8F85-B1C894C7DECCQ36861707-C5AE4C10-275C-44E5-80AA-B317CBD1BD87Q36881446-B0D7A1F3-1989-4448-BA06-B50E0CFF940BQ36971953-75F57481-194C-41C8-B494-4DB6A99C827DQ37178822-73777BBB-0A7E-412E-8056-F38E91A9335EQ37230991-7F572F98-757C-4CBF-9B71-E21621E8BE78Q37611396-CA90DA04-0BCF-4D65-8272-0A804C742BF8Q37673528-79C4C5AA-3E3A-4CD3-85C5-C819B79C624FQ38044219-9D913BE9-39C6-447F-BD51-C1A241D87499Q38199723-215BAF1E-D9AB-4445-9657-4BB29BED3CF0Q38204280-7E6948DD-03E0-4E6F-94E9-1E0429EA9028Q38842731-C7F75ADB-41E0-4B51-B134-025F33C60180Q39051424-53F98DF5-7BF5-48AF-8134-ACD59C6D173EQ39453577-B19ED2F8-B440-4EAC-B01B-1BAA7770EC41Q43128355-70A19284-90FC-4EEF-A947-1C63B2A6C26AQ51045630-69983145-B9A4-44A7-A6F7-0EDA9648319EQ52571053-9A18064C-B822-46C7-93FC-F31B56A78992Q55099689-1BFB1C2F-4FBD-4796-8257-C61E3FAEEE71
P2860
The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
The gamma secretase inhibitor ...... growth in preclinical models.
@en
The gamma secretase inhibitor ...... growth in preclinical models.
@nl
type
label
The gamma secretase inhibitor ...... growth in preclinical models.
@en
The gamma secretase inhibitor ...... growth in preclinical models.
@nl
prefLabel
The gamma secretase inhibitor ...... growth in preclinical models.
@en
The gamma secretase inhibitor ...... growth in preclinical models.
@nl
P2093
P2860
P1476
The gamma secretase inhibitor ...... growth in preclinical models.
@en
P2093
Anirban Maitra
Elizabeth De Oliveira
Masamichi Mizuma
N V Rajeshkumar
Nathaniel R Campbell
Noriyuki Omura
Oscar Puig
Qing Zhang
Roeland F de Wilde
Shinichi Yabuuchi
P2860
P304
P356
10.1158/1535-7163.MCT-12-0017
P577
2012-07-02T00:00:00Z